Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized, double-blind, placebo-controlled, 12-month study to determine the effectiveness of D-mannose (2g daily) supplementation in rUTI (recurrent urinary tract infection) prevention in post-menopausal women.
The proposed study on D-mannose prophylaxis is designed to address a critical unmet medical need to improve the understanding and prevention of rUTI (recurrent urinary tract infection) in post-menopausal women, a population disproportionately affected by rUTI and understudied. The efficacy of D-mannose on preventing uncomplicated rUTI will be elucidated, and additional study measures (including urine culture and one-hour D-mannose test results) may help establish an ideal candidate for responding to daily D-mannose intake over time. The proposed study will follow CONSORT guidelines for randomized clinical trial studies.
Aim 1. Test the hypothesis that D-mannose provides effective rUTI prophylaxis in post-menopausal women over 6 months.
Aim 2. Test the hypothesis that D-mannose provides effective rUTI prophylaxis in post-menopausal women beyond 6 months and up to one year.
The overarching hypotheses are that (1) D-mannose will be found superior to placebo in preventing rUTI in post-menopausal women over 6 months as suggested by one prior RCT7 (Aim 1) and (2) D-mannose will remain effective for rUTI prophylaxis up to one year (Aim 2).
Ninety (90) women currently UTI-free and with a history of uncomplicated rUTI, defined as ≥ 2 symptomatic UTIs in 6 months or ≥ 3 symptomatic UTIs in 12 months, will be enrolled and randomized (2:1 ratio) to receive D-mannose (2g, i.e., 4 x 500mg capsules) or placebo daily for 12 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| D-mannose | Active Comparator | Dietary Supplement: D-Mannose |
|
| Placebo | Placebo Comparator | Dietary Supplement: Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| D-Mannose | Dietary Supplement | D-mannose (2g, i.e., 4 x 500mg capsules) daily for 12 months. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Failure rate | To determine whether prophylaxis with D-mannose reduces the incidence of UTI episodes compared to placebo. "Failure rate," defined as having 2 UTIs in 6 months or 3 in one year. | Through study completion, an average of 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of UTI antibiotic treatments | To investigate if D-mannose reduces the need for antibiotic use due to recurrent UTIs (measured as number of antibiotic courses for symptomatic culture-proven UTI episodes) compared to placebo. Number of UTI antibiotic treatments during the 6 months of treatment. If the participant receives >1 antibiotic course for UTI without symptom relief, it is regarded as one episode and counted as one antibiotic treatment. If there has been an asymptomatic period of at least 14 days in between two UTI antibiotic courses, this will be regarded as a new antibiotic treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Box 1 Supplements to avoid
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jessica de Araujo Paula | Contact | 2146458787 | jessica.dearaujopaula@utsouthwestern.edu | |
| Meghan Leak | Contact | 2146458787 | meghan.leak@utsouthwestern.edu |
| Name | Affiliation | Role |
|---|---|---|
| Philippe Zimmern, MD | University of Texas Southwestern Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas Southwestern Medical Center | Recruiting | Dallas | Texas | 75390 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
D-mannose and placebo
Not provided
Not provided
Not provided
| Placebo |
| Dietary Supplement |
Placebo daily for 12 months. |
|
| Through study completion, an average of 5 years |
| Symptom severity | To investigate if D-mannose reduces the severity of UTI symptoms compared to placebo. Record symptom severity using a validated UTI symptom assessment questionnaire. | Through study completion, an average of 5 years |
| Serious adverse events associated with D-mannose | To determine the frequency of serious adverse events associated with D-mannose. Number of participants who experienced adverse events >= Grade 3, as defined by Common Terminology Criteria for Adverse Events by CTCA version 5.0. | Through study completion, an average of 5 years |
| ID | Term |
|---|---|
| D014552 | Urinary Tract Infections |
| D003556 | Cystitis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008358 | Mannose |
| ID | Term |
|---|---|
| D006601 | Hexoses |
| D009005 | Monosaccharides |
| D000073893 | Sugars |
| D002241 | Carbohydrates |
Not provided
Not provided